热门资讯> 正文
Surmodics超出了顶线和底线估计;暂停年度指导
2024-07-31 20:53
- Surmodics press release (NASDAQ:SRDX): Q3 Non-GAAP EPS of -$0.27 beats by $0.06.
- Revenue of $30.3M (-42.3% Y/Y) beats by $0.29M.
- Adjusted EBITDA was $1.6M, compared to Adjusted EBITDA of $24.6M in the third quarter of fiscal 2023.
- As of June 30, 2024, Surmodics reported $38.2M in cash and investments, $5M in outstanding borrowings on its revolving credit facility, and $25M in outstanding borrowings on its term loan facility.
- The company is suspending its previously issued financial guidance for fiscal 2024 in light of the pending acquisition by GTCR.
More on Surmodics
- Surmodics jumps 18% on acquisition by GTCR
- Seeking Alpha’s Quant Rating on Surmodics
- Historical earnings data for Surmodics
- Financial information for Surmodics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
